Financial Summary for the Six Months Ended March 31, 2027 (Interim) [Japanese GAAP] (Consolidated)

Overview of Results

This financial summary discloses consolidated results for the six months ended March 31, 2027. Revenue totaled 7,259 million yen, a substantial increase of 38.6% year-over-year. Meanwhile, operating income was 527 million yen (vs. 546 million yen in the same period last year), ordinary income was 511 million yen, and interim net income attributable to owners of parent was 296 million yen, all below the prior-year period. Revenue growth was driven by expansion in both AI products and AI solution services, but increased investment led to higher depreciation and system costs, which pressured profits. The financial position remains healthy with total assets of 14,953 million yen, an equity ratio of 68.6%, and cash and deposits of 8,177 million yen.

Outlook and Organizational Developments

Full-year forecasts remain unchanged. The company changed the scope of consolidation for four new subsidiaries and prepared interim consolidated financial statements, and executed multiple organizational restructurings (absorption-type splits, spin-offs, and establishment of subsidiaries) to optimize the portfolio centered on AI products and accelerate growth. In particular, the establishment/acquisition of entities such as Exa Frontier Edge will strengthen AX initiatives and collaboration in the medical and nursing care fields.